Several studies have reported that patients carrying R92Q tend to present with milder disease phenotype and better long-term prognosis compared with those carrying structural or pathogenic TNFRSF1A mutations, who usually suffer from more severe manifestations and long-term complications (e.g., amyloidosis) (4–11, 18). The gene discussed is TNFRSF1A; the disease is amyloidosis.